Fels Cancer Institute for Personalized Medicine, Fox Chase Cancer Center, and Thomas Jefferson University to Host Inaugural Symposium on Genome Instability and Personalized Medicine

Tomasz Skorski, MD, PhD, DSc, director of the Fels Cancer Institute and associate director at Fox Chase
Tomasz Skorski, MD, PhD, DSc, director of the Fels Cancer Institute and associate director at Fox Chase

PHILADELPHIA (August 4, 2022)—The Fels Cancer Institute for Personalized Medicine at the Lewis Katz School of Medicine at Temple University, in partnership with Fox Chase Cancer Center and Thomas Jefferson University, will host a free symposium, “Genome Instability: Discovery to Personalized Medicine.” This event will be held in person on Friday, October 14, 2022, at the DoubleTree by Hilton hotel in Philadelphia.

“The inaugural symposium will feature world-leading scientists and clinicians studying basic mechanisms of genome biology as well as personalized medicine” said Tomasz Skorski, MD, PhD, DSc, director of the Fels Cancer Institute and associate director at Fox Chase. “Speakers will cover topics ranging from basic mechanisms to clinical targeting of DNA repair enzymes.”

Skorski, Neil Johnson, PhD, an associate professor in the Molecular Therapeutics research program at Fox Chase, and Richard Pomerantz, PhD, an associate professor in the Department of Biochemistry and Molecular Biology at Jefferson, are jointly chairing the event. The symposium will feature keynote speaker Mark O’Connor, PhD, chief scientist, DNA Damage Response in Oncology R&D at AstraZeneca.

Speakers will also include faculty from the Perelman School of Medicine and Abramson Cancer Center at the University of Pennsylvania, Yale School of Medicine, National Institute of Aging at NIH, University of Massachusetts Chan Medical School, University of Florida Health Cancer Center, Laval University, University of Texas Health San Antonio, and The Wistar Institute.

Skorski said those with an interest in the most up-to-date advances in the DNA repair field and novel therapeutic approaches for cancer should attend, including undergraduate and graduate students, postdoctoral associates, professors, physicians, and members of the pharmaceutical industry.

The program will run from 8:20 a.m. to 5:30 p.m. The event is free, but preregistration is required.

For more details, including a full list of speakers, and to register, visit the event page.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427